Health

30 articles

Long-Term Study: Tirzepatide Cuts Diabetes Risk by 94% in Prediabetes
Health2026-11-13

Long-Term Study: Tirzepatide Cuts Diabetes Risk by 94% in Prediabetes

New data from Eli Lilly's SURMOUNT-1 trial show that tirzepatide, the active ingredient in Mounjaro and Zepbound, reduced the risk of progression to type 2 diabetes by 94% in overweight or obese adults with prediabetes over three years. Even after a 17-week washout, the risk reduction remained at 88%, suggesting lasting benefits. The findings, not yet peer-reviewed, add to the growing evidence on GLP-1-type medications.